The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort
Open accessAbstract
Introduction: The objective of the present study was to examine the association of baseline demographic and clinical characteristics with sequentially obtained measurements of forced vital capacity (FVC), expressed as a percentage of the predicted value, and to identify predictors of the decline rate in FVC over time in the Genetics versus Environment in Scleroderma Outcome Study (GENISOS). Methods: To date, 266 patients have been enrolled in GENISOS, a prospective, observational cohort of patients with early systemic sclerosis. In addition to pulmonary function tests (PFTs), clinical and laboratory data were obtained from each patient. We analyzed 926 FVC measurements utilizing generalized linear mixed models. The predictive significance of baseline variables for the decline rate in FVC was investigated by the interaction term between the variable and the follow-up time within the first 3 years after enrollment as well as throughout the entire follow-up time. Results: The cohort consisted of 125 white, 54 African American, and 77 Hispanic patients with average disease duration of 2.5 years at enrollment. The mean follow-up time was 3.8 years, ranging up to 11.4 years. A number of baseline variables, including antibody status, African American ethnicity, disease type, baseline PFT values, modified Rodnan Skin Score, fibrosis on chest radiograph, and lung and skin subscores of the Severity Index, were associated with serially measured FVC levels. However, only the presence of anti-topoisomerase I antibodies (ATA) was associated with lower FVC levels (P < 0.001) as well as accelerated decline rate in FVC within the first 3 years of follow-up (P = 0.02). None of the baseline variables predicted the rate of decline in FVC on long-term follow-up. Patients with rapidly progressive ILD, however, were under-represented in the long-term follow-up group because the accelerated rate of decline in FVC was associated with poor survival (P = 0.001). Conclusions: Presence of ATA was the only baseline variable associated with differential FVC levels, predicting the rate of decline in FVC within the first 3 years of follow-up. The association of faster decline in FVC with poor survival further emphasizes the need for identification of predictive biomarkers by collection of genetic information and serial blood samples in cohort studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Standardisation of the measurement of lung volumes
Wanger, J., Clausen, J. L., Coates, A., Pedersen, O. F., Brusasco, V., Burgos, F., Casaburi, R., Crapo, R., Enright, P., van der Grinten, C. P. M., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00035005 · Cited by 2,768
Coping with rheumatoid arthritis pain: catastrophizing as a maladaptive strategy
Keefe, F. J., Brown, G. K., Wallston, K. A., & Caldwell, D. S. (1989) · Pain · doi:10.1016/0304-3959(89)90152-8 · Cited by 694 · cited 1×
“Systemic sclerosis (SSc) is associated with substantial morbidity and mortality [1,2], and leads to detrimental effects on health-related quality of life [3].”
Background
Cited by
Nintedanib for systemic sclerosis–associated interstitial lung disease
Distler, O., Highland, K. B., Gahlemann, M., Azuma, A., Fischer, A., Mayes, M. D., Raghu, G., Sauter, W., Girard, M., Alves, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903076 · Cited by 1,647
Self-citationPrediction of Pulmonary Complications and Long‐Term Survival in Systemic Sclerosis
Nihtyanova, S. I., Schreiber, B. E., Ong, V. H., Rosenberg, D., Moinzadeh, P., Coghlan, J. G., Wells, A. U., & Denton, C. P. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38390 · Cited by 460
Hoffmann-Vold, A.-M., Allanore, Y., Alves, M., Brunborg, C., Airó, P., Ananieva, L. P., Czirják, L., Guiducci, S., Hachulla, E., Li, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217455 · Cited by 357
Jaeger, V. K., Wirz, E. G., Allanore, Y., Rossbach, P., Riemekasten, G., Hachulla, E., Distler, O., Airò, P., Carreira, P. E., Balbir Gurman, A., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163894 · Cited by 268
Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort
Hoffmann-Vold, A.-M., Fretheim, H., Halse, A.-K., Seip, M., Bitter, H., Wallenius, M., Garen, T., Salberg, A., Brunborg, C., Midtvedt, Ø., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0486oc · Cited by 257
Metadata
- Authors
- Assassi, S., Sharif, R., Lasky, R. E., McNearney, T. A., Estrada-Y-Martin, R. M., Draeger, H., Nair, D. K., Fritzler, M. J., Reveille, J. D., Arnett, F. C., Mayes, M. D., & the GENISOS Study Group
- Venue
- Arthritis Research & Therapy
- Published
- 2010-09-02
- Volume
- 12
- Issue
- 5
- Pages
- R166-R166
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2119115210
- Cited by
- 180
- References
- 3
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.